Form 4: Relmada Therapeutics CFO Maged Shenouda Increases Stake in Company
SEC Form 4 Filing
Maged Shenouda, CFO of Relmada Therapeutics, recently acquired a significant number of common stock shares through open market purchases.
Summary
- On May 16, 2025, Maged Shenouda, the CFO of Relmada Therapeutics, purchased 50,000 shares of common stock at a weighted average price of $0.442 per share.
- On May 19, 2025, Shenouda acquired an additional 90,000 shares at a weighted average price of $0.4854 per share.
- On May 20, 2025, Shenouda further increased his holdings by purchasing 60,000 shares at a weighted average price of $0.5237 per share.
- Following these transactions, Shenouda directly owns 288,335 shares of Relmada Therapeutics common stock.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the CFO's increased investment in the company, which suggests confidence in its future.
Positives
- The CFO's increased investment in the company may signal confidence in Relmada Therapeutics' future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company insider believes the company's stock is undervalued.
Stakeholder Impact
- Shareholders may view the CFO's stock purchases as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | CFO purchased 50,000 shares of common stock. |
| 05/19/2025 | CFO purchased 90,000 shares of common stock. |
| 05/20/2025 | CFO purchased 60,000 shares of common stock; Form 4 filing date. |
Keywords
Relmada Therapeutics, RLMD, Maged Shenouda, CFO, stock purchase, Form 4, insider trading, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.